IL12 antibody

Catalog No. ABIN1177266

Product Details anti-IL12 Antibody

Target: IL12 (Interleukin 12 (IL12))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IL12 antibody is un-conjugated

Application: ELISA, Neutralization (Neut)

Brand: BD Pharmingen™

Characteristics: Neutralization Activity: This antibody has been reported to be useful for the neutralization of human IL-12 (p70) bioactivity. Neutralization may be measured with a proliferation assay using 200 pg/mL recombinant human IL-12 (p70) (Cat. No. 554613) to stimulate human PBMC as indicator cells (i.e. preincubation of the antibody with recombinant human IL-12 (p70) for 60 minutes).
50% Neutralization (ND50) at 10-300 ng/mL
>95% Neutralization at 1-20 µg/mL

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Sterility: 0.2 μm filtered

Endotoxin Level: Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.

Immunogen: Purified p40 Subunit of Human IL-12

Clone: C8-6

Isotype: IgG1 kappa

Application Details

Application Notes: ELISA (IL-12 p70 Detection): The biotinylated C8.6 (Cat. No. 554660) antibody is useful as a detection antibody in sandwich ELISA for measuring human IL-12 (p70). Biotinylated C8.6 antibody can be paired with the purified 20C2 antibody (Cat. No. 555065) as the capture antibody and recombinant human IL-12 (p70) protein (Cat. No. 554613) as the standard. For testing human IL-12 (p70) in complex biological fluids, such as serum or plasma, investigators may wish to consider using the BD OptEIA™ Human IL-12 (p70) ELISA Set (Cat. No. 555183). ELISA (IL-12 p40 Detection): The biotinylated C8.6 (Cat. No. 554660) antibody is useful as a detection antibody in sandwich ELISA for measuring human IL-12 (p40). Biotinylated C8.6 antibody can be paired with the purified C8.3 antibody (Cat. No. 551227) as the capture antibody with recombinant human IL-12 (p40) protein (Cat. No. 554633) as the standard. For testing human IL-12 (p40) in complex biological fluids, such as serum or plasma, investigators may wish to consider using the BD OptEIA™ Human IL-12 (p40) ELISA Set (Cat. No. 555171).

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.

Preservative: Azide free

Storage: 4 °C

Storage Comment: Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

References for anti-IL12 antibody (ABIN1177266)

Oppmann, Lesley, Blom, Timans, Xu, Hunte, Vega, Yu, Wang, Singh, Zonin, Vaisberg, Churakova, Liu, Gorman, Wagner, Zurawski, Liu, Abrams, Moore, Rennick, de Waal-Malefyt, Hannum, Bazan, Kastelein: "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12." in: Immunity, Vol. 13, Issue 5, pp. 715-25, (2001) (PubMed).

DAndrea, Aste-Amezaga, Valiante, Ma, Kubin, Trinchieri: "Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells." in: The Journal of experimental medicine, Vol. 178, Issue 3, pp. 1041-8, (1993) (PubMed).

DAndrea, Rengaraju, Valiante, Chehimi, Kubin, Aste, Chan, Kobayashi, Young, Nickbarg: "Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells." in: The Journal of experimental medicine, Vol. 176, Issue 5, pp. 1387-98, (1992) (PubMed).

Target Details for IL12

Target: IL12 (Interleukin 12 (IL12))

Alternative Name: IL-12 (p40/p70) (IL12 Products)

Background: The C8.6 antibody reacts with human IL-12 p40 monomers, homodimers, and p70 heterodimers, but not p35 subunits. The immunogen used to generate the C8.6 hybridoma was the purified p40 subunit of human IL-12. The C8.6 antibody is a neutralizing antibody and has been reported to strongly inhibit three different biological activities of IL-12 (i.e., IFN-gamma induction), mitogenic effects on PHA blasts, and enhancement of NK cell-mediated cytotoxicity. C8.6 has been shown to immunoprecipitate IL-23.

Pathways: JAK-STAT Signaling, TLR Signaling, Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Activated T Cell Proliferation, Cancer Immune Checkpoints, Inflammasome